When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

University of Pennsylvania and Syracuse University scientists have discovered that a hindbrain-derived peptide, octadecaneuropeptide (ODN), can suppress appetite and improve glucose regulation without ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

Body-acceptance advocate Katie Sturino and Ronald Young Jr., host of the podcast Weight for It, answer listener questions ...

New study reveals adding whey protein to dual-source carbohydrates enhances amino acid availability without compromising ...

Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, ...

GLP-1 RAs are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin.

For patients with idiopathic intracranial hypertension, GLP-1 RA treatment is linked to improved clinical outcomes compared with conventional therapies.

For older adults with diabetes, there is no evidence to suggest that the incidence of dementia differs for those using GLP-1 RAs vs DPP4is.

For adults with type 2 diabetes and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality.